| Literature DB >> 28820965 |
Daniela M Arduino1, Jennifer Wettmarshausen1, Horia Vais2, Paloma Navas-Navarro3, Yiming Cheng1, Anja Leimpek1, Zhongming Ma2, Alba Delrio-Lorenzo3, Andrea Giordano1, Cecilia Garcia-Perez1, Guillaume Médard4, Bernhard Kuster5, Javier García-Sancho3, Dejana Mokranjac6, J Kevin Foskett7, M Teresa Alonso3, Fabiana Perocchi8.
Abstract
The mitochondrial calcium uniporter complex is essential for calcium (Ca2+) uptake into mitochondria of all mammalian tissues, where it regulates bioenergetics, cell death, and Ca2+ signal transduction. Despite its involvement in several human diseases, we currently lack pharmacological agents for targeting uniporter activity. Here we introduce a high-throughput assay that selects for human MCU-specific small-molecule modulators in primary drug screens. Using isolated yeast mitochondria, reconstituted with human MCU, its essential regulator EMRE, and aequorin, and exploiting a D-lactate- and mannitol/sucrose-based bioenergetic shunt that greatly minimizes false-positive hits, we identify mitoxantrone out of more than 600 clinically approved drugs as a direct selective inhibitor of human MCU. We validate mitoxantrone in orthogonal mammalian cell-based assays, demonstrating that our screening approach is an effective and robust tool for MCU-specific drug discovery and, more generally, for the identification of compounds that target mitochondrial functions.Entities:
Keywords: MCU; bioenergetics; calcium; calcium signaling; drug discovery; drug screening; high-throughput screening; mitochondria; mitochondrial calcium uniporter
Mesh:
Substances:
Year: 2017 PMID: 28820965 PMCID: PMC5825229 DOI: 10.1016/j.molcel.2017.07.019
Source DB: PubMed Journal: Mol Cell ISSN: 1097-2765 Impact factor: 17.970